FDA: Nearly Half of Cell and Gene Therapy Submissions Delayed by Manufacturing Issues

**FDA Letters Highlight Manufacturing Challenges for Cell and Gene Therapies**

Nearly half of all cell and gene therapy submissions face setbacks due to FDA complete response letters, which identify manufacturing strategy and process design as recurring regulatory obstacles. These challenges represent the industry’s most consistent vulnerabilities in the approval process.

The FDA issues complete response letters when a therapy application does not meet the agency’s standards for approval. The high rate of these letters in the cell and gene therapy sector underscores the critical need for robust and well-defined manufacturing strategies and process designs to ensure regulatory compliance and successful market entry.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI